Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 770 participants.
Also called NCT02304484
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 770 participants
- Sponsor
- Registry
-
NCT02304484 -
2014-001524-30
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, Norway, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02304484. Allocation not applicable; no masking; primary purpose treatment. Start 2014-11-24 (actual); primary completion 2018-03-09 (actual). Results posted on 2019-03-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
- Condition
- Hypercholesterolemia
- Intervention (Biological)
- Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02304484- Content hash
e00cfd5770f3cf42721c1af38be3f7f985fb03371d6402d337e7c51194dbf791